A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — NATiV3

NASH - Nonalcoholic Steatohepatitis Clinical Trial

Official title:
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3

Status Recruiting

Clinical Trial Summary

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Clinical Trial Description

Primary objectives This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts - an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives: Part A To assess the safety and efficacy of lanifibranor compared to placebo on 'NASH resolution and improvement of fibrosis' assessed by liver histology. Part B To assess the safety of lanifibranor beyond the DBPC period. Secondary objectives Key secondary objectives of Part 1: - To assess the effect of lanifibranor compared to placebo on NASH resolution and no worsening of fibrosis - To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with no worsening of NASH Other secondary objectives of both Part 1 and Part 2: - To assess the effect of lanifibranor on other key histological features of NASH (only for DBPC period) - To assess the effect of lanifibranor on NASH resolution and improvement of fibrosis in diabetic patients (only for DBPC period) - To assess the effect of lanifibranor on liver tests - To assess the effect of lanifibranor on glycaemic parameters - To assess the effect of lanifibranor on lipid parameters - To assess the effect of lanifibranor on liver stiffness and steatosis assessed by elastography. - To assess the effect of lanifibranor on health-related quality of life - To assess the safety of lanifibranor - To assess population PK modeling through plasma levels of lanifibranor using sparse sampling scheme (only for DBPC period) ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Fibrosis
NASH - Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT04849728
Study type	Interventional
Source	Inventiva Pharma
Contact	Pascaline Clerc
Phone	2024998937/0644637545
Email	clinical.contact@inventivapharma.com
Status	Recruiting
Phase	Phase 3
Start date	August 19, 2021
Completion date	September 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03289897` - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan	N/A
Active, not recruiting	`NCT05479721` - LITMUS Imaging Study
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Recruiting	`NCT04976283` - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver	Phase 4
Completed	`NCT02784444` - A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH	Phase 2
Not yet recruiting	`NCT05499949` - The Franciscus Obesity NASH Study
Completed	`NCT04321343` - Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)	Phase 2
Recruiting	`NCT04371042` - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Not yet recruiting	`NCT03648554` - Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)	Phase 4
Completed	`NCT04972396` - ALT-801 DDI Study in Healthy Volunteers	Phase 1
Completed	`NCT03748628` - Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects	Phase 1
Enrolling by invitation	`NCT05195944` - Semaglutide vs Sitagliptin	Phase 4
Completed	`NCT04643795` - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects	Phase 1
Terminated	`NCT03669133` - Vitamin E for NASH Treatment in HIV Infected Individuals	Phase 2
Completed	`NCT04066400` - Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis	N/A
Completed	`NCT03536650` - Effect of DMR in the Treatment of NASH	N/A
Completed	`NCT03783897` - A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects	Phase 1
Completed	`NCT04618744` - A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)	Phase 2
Active, not recruiting	`NCT05338034` - Phase 2a Study of HPG1860 in Subjects With NASH	Phase 2
Active, not recruiting	`NCT04653103` - NASH in Subjects With Different Classes of Obesity

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.